Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interventional cardiovascular pharmacotherapy: current issues.

Abdallah G Rebeiz1, Joseph Adams, Robert A Harrington

  • 1Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA. rebei001@mc.duke.edu

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|February 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sexually transmitted infection prevalence and Neisseria gonorrhoeae antimicrobial resistance patterns in men who have sex with men with or without urethral discharge syndrome in Johannesburg, South Africa, 2024.

PLOS global public health·2026
Same author

Topical administration of in situ gelling formulation containing myricetin-polycarboxylate nanoparticles inhibits murine genital herpes infection.

International journal of pharmaceutics·2026
Same author

Smaller glenosphere size and increased baseplate retroversion improve postoperative internal rotation after reverse total shoulder arthroplasty performed with a 135° humeral implant and lateralized glenoid.

JSES international·2026
Same author

Heme drives cardiac endothelial senescence in sepsis via STING activation.

Cell death & disease·2025
Same author

HSPA12B Protects Against Age-Related Endothelial Cell Senescence by Regulating STING Degradation.

Aging cell·2025
Same author

β-Glucan Protects Against Sepsis-Induced Kupffer Cell Loss by Inhibiting Pyroptosis and Promoting Self-Renewal.

Immunology·2025

Optimal antithrombotic strategies are crucial for patients undergoing percutaneous coronary intervention (PCI). Evidence supports using specific anticoagulants and antiplatelet agents, like glycoprotein IIb/IIIa inhibitors, to reduce thrombotic events and improve outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Novel anticoagulant and antiplatelet agents have improved outcomes in percutaneous coronary revascularization (PCI).
  • Advancements in catheter-based devices will increase PCI procedures.
  • Optimal antithrombotic strategies are key to reducing adverse events during PCI.

Purpose of the Study:

  • To review the current evidence on the efficacy of adjunctive anticoagulant and antiplatelet agents in PCI.
  • To highlight the need for tailored antithrombotic strategies based on patient risk and device type.

Main Methods:

  • Review of current evidence regarding anticoagulant and antiplatelet agents used in percutaneous coronary revascularization.
  • Discussion of specific antithrombotic strategies for different patient populations (e.g., acute coronary syndrome vs. stable angina).

Related Experiment Videos

  • Consideration of device-specific anticoagulation needs (e.g., angioplasty vs. brachytherapy).

    • Main Results:

    • Activated clotting times should be targeted between 200-250 seconds for elective PCI and 250-300 seconds for higher-risk lesions or acute coronary syndrome (ACS).
    • Low-dose enoxaparin sodium is a suitable antithrombin strategy in PCI, adjusting for renal function, age, and GP IIb/IIIa antagonist use.
    • Glycoprotein (GP) IIb/IIIa antagonists are strongly supported in ACS patients, reducing thrombotic complications and mortality post-PCI, but not restenosis.

    Conclusions:

    • Tailored antithrombotic regimens are essential for effective and safe percutaneous coronary intervention.
    • Glycoprotein IIb/IIIa inhibitors offer significant benefits for high-risk ACS patients undergoing PCI.
    • Further research may be needed to optimize antithrombotic strategies for evolving catheter-based devices.